# China biotech
Latest news and articles about China biotech
Total: 7 articles found
Bispecific ADC Combined with PD‑1 Inhibitor Shows Promising Frontline Activity in Extensive‑Stage Small‑Cell Lung Cancer
A phase II trial in China led by Prof. Zhou Caicun reports that the EGFR×HER3 bispecific ADC iza‑bren combined with a domestic PD‑1 inhibitor (Sru‑li) produced a median PFS of 8.2 months and a one‑year OS rate of 85.7% as first‑line therapy for extensive‑stage small‑cell lung cancer. The results are promising compared with historical chemo‑immunotherapy benchmarks but require validation in larger, randomized studies with full safety data.
China CRO ‘Hoards Monkeys, Sells Shares’: Major Holders Exit as Zhaoyan’s Earnings Mask Weak Core Business
Zhaoyan New Drug saw its shares tumble after major shareholders announced plans to sell their entire holdings, triggering a market rout. The company’s improved 2025 net profit projection is driven largely by non‑cash fair‑value gains on biological assets, while its core CRO business faces revenue decline and negative operating profit amid sector overcapacity and price competition.
CCTV Spotlight Sinks Credibility of Zhengzhou Biotech as Multiple Patents Rejected
CCTV’s consumer‑rights programme named Zhengzhou Yuanchuang Gene in a probe of overhyped exosome products, and public records show several of the company’s patent applications have been rejected. The development highlights the tension between genuine exosome research and a market of unproven claims, and signals heightened regulatory and reputational risks for small biotech firms in China.
From Test Kits to First‑in‑Class Drugs: Hotgen’s Bid to Anchor ‘Healthy China’ in Home‑grown Biotech
Hotgen Biotech is pursuing a dual diagnostics‑and‑innovative‑drug strategy to back China’s Healthy China goals, advancing an antibody for acute myocardial infarction, SGC001, into Phase II. The effort exemplifies China’s broader shift from following foreign pharmaceutical models to developing first‑in‑class domestic innovations, but faces clinical, manufacturing and regulatory hurdles before it can transform national health and global competitiveness.
China Installs First Superconducting Linac for Mass Production of Scarce Alpha Cancer Isotopes
China’s Institute of Modern Physics has installed the main accelerator for IP-SAFE, a superconducting linac demonstrator intended to mass-produce scarce alpha-emitting isotopes Ac-225 and Ra-223. The facility aims to ease global shortages that constrain targeted alpha therapies and to bolster domestic biomedical and accelerator capabilities.
Chinese Drugmaker Huadong Advances RNAi Weight‑loss Candidate into Preclinical Studies
Huadong Medicine and Suzhou Shian Biotech have confirmed a preclinical siRNA candidate aimed at an innovative weight‑loss mechanism and entered preclinical research. The move underscores China’s push into RNAi therapeutics for metabolic disease, but substantial scientific, delivery and regulatory challenges lie ahead before any clinical testing.
China CRO Pumps Profits by Stockpiling Lab Monkeys and Cash — but Sustainability Is in Doubt
Zhaoyan New Drug posted a paradoxical 2025 outlook: lower revenue but sharply higher net profit driven mainly by fair‑value gains on biological assets — chiefly experimental monkeys — and returns from cash management. The company’s core laboratory services remain under pressure, and the profitability bump has prompted scrutiny about the sustainability of relying on asset revaluation and financial income rather than scientific capabilities.